The multiple level of interactions that exist in EGF signaling, RAS, and cell survival, proliferation and invasion, indicated that high plasma TIMP-1 levels may interact with EGFR signaling and thereby affect the anti-tumor effects of EGFR inhibitors. The gene discussed is EGFR; the disease is neoplasm.